EGFR and breast cancer: The effect of the molecules 25 and 27 in cell cycle progression, a key event downstream of EGFR/PI3K pathway [45], was assessed by immunocytochemistry analysis of cyclin D2 (Figure 6), a protein involved in cell cycle progression and described to be downregulated in BC [31,46].